Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Renalytix PLC
Total Liabilities & Equity
Renalytix PLC
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Renalytix PLC
LSE:RENX
|
Total Liabilities & Equity
$6.1m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Total Liabilities & Equity
$525.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
34%
|
CAGR 10-Years
21%
|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Total Liabilities & Equity
£11.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Feedback PLC
LSE:FDBK
|
Total Liabilities & Equity
£4.9m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
27%
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Total Liabilities & Equity
£17.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
P
|
Physitrack PLC
STO:PTRK
|
Total Liabilities & Equity
€19.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Total Liabilities & Equity?
Total Liabilities & Equity
6.1m
USD
Based on the financial report for Dec 31, 2025, Renalytix PLC's Total Liabilities & Equity amounts to 6.1m USD.
What is Renalytix PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-44%
Over the last year, the Total Liabilities & Equity growth was -45%. The average annual Total Liabilities & Equity growth rates for Renalytix PLC have been -48% over the past three years , -44% over the past five years .
